{"page":{"totalFilteredElements":385},"studies":[{"active":true,"description":"Niraparib vs. Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicenter randomised phase III trial)","eudractNumber":"2024-516066-11-00","id":8116,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05009082","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2022-10-21T11:30:38+02:00","shortTitle":"AGO-Ovar 28","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"Randomisierte Studie zur Evaluation der Wirksamkeit einer Cetuximab-Reexposition bei Patienten mit metastasiertem kolorektalem Karzinom (RAS Wildtyp), welche auf eine Erstlinien-Behandlung mit FOLFIRI plus Cetuximab ein Ansprechen zeigten","eudractNumber":"2014-003787-21","id":2884,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ras-Gen","id":"mt_28"},{"name":"NRAS","id":"mt_6"},{"name":"KRAS","id":"mt_7"}],"nctNumber":"NCT02934529","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2017-02-17T12:22:59+01:00","shortTitle":"AIO-KRK-0114/ FIRE-4","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Prospektive, randomisierte, offene, multizentrische Phase III Studie zur Untersuchung der Wirksamkeit einer Therapie in Patienten mit metastasiertem kolorektalen Karzinom, nach erfolgter Resektion oder Ablation<div><b>DRKS00027138</b><br /></div>","eudractNumber":"2020-006144-18","id":7450,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-11-17T14:29:54+01:00","shortTitle":"AIO-KRK-0418 / FIRE-9 - PORT","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Prospektive, randomisierte, offene, multizentrische Phase II Studie zur Untersuchung der Wirksamkeit von Tifluridin/Tipiracil plus Panitumumab im Vergleich zu Tifluridin/ Tipiracil plus Bevacizumab bei der Erstlinientherapie des metastasierten kolorektalen Karzinoms","eudractNumber":"2019-004223-20","id":7571,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ras-Gen","id":"mt_28"}],"nctNumber":"NCT05007132","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2021-12-09T09:07:50+01:00","shortTitle":"AIO-KRK/YMO-0519 (Fire-8)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study \nEvaluating The Safety And Efficacy Of Efruxifermin (EFX) In Subjects with Non-Cirrhotic Non-alcoholic Steatohepatitis (NASH) \nAnd Fibrosis","eudractNumber":"2023-505141-48-00","id":9598,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06215716","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-03-28T08:46:05+01:00","shortTitle":"AK-US-001-0105","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"International cooperative study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of vinblastine<br />","eudractNumber":"2017-002935-40","id":4034,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped2","name":"Lymphome"}],"mutations":[{"name":"ALK","id":"mt_11"}],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-04-14T09:44:08+02:00","shortTitle":"ALCL-VBL","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>ALL SCT FORUM Registry 2022</div><div>Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia</div>","eudractNumber":null,"id":9804,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2024-10-01T08:39:44+02:00","shortTitle":"ALL SCT FORUM Registry 2022","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Beobachtungsstudie und Biobank f&#252;r Rezidive einer akuten lymphoblastischen Leuk&#228;mie im Kindes- und Jugendalter<br />","eudractNumber":null,"id":656,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2012-10-01T09:06:33+02:00","shortTitle":"ALL- REZ BFM","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"ALL-BFM-Register zur Erfassung von Daten von Kindern und Jugendlichen mit akuter lymphoblastischer Leuk&#228;mie in Deutschland","eudractNumber":null,"id":10535,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2025-01-17T13:12:17+01:00","shortTitle":"ALL-BFM Register","therapeutical":true,"therapyLines":[]},{"active":true,"description":"<div>A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator&#8217;s Choice in Participants with Chemotherapy-na&#239;ve Metastatic Castration-resistant Prostate Cancer</div>","eudractNumber":"2025-520555-89","id":11331,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07213674","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-15T10:26:05+01:00","shortTitle":"AMG 509 20230239","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]}]}